FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and concerns a composition for treating hepatitis C and a method of treating hepatitis C. Substance of the inventions involves the composition for treating hepatitis C consisting of dendritic cells produced of patient's monocytes with NS3 protein fragments and activated patient's T-lymphocytes with the NS3 protein fragments containing the sequence 1027-1218. The method of treating involves injection of the prepared composition into the patient.
EFFECT: advantage of the inventions consists in preparing the composition for treating hepatitis C and the method of treating hepatitis C, including a chronic form.
10 cl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR IMMUNE THERAPY OF CHRONIC VIRAL HEPATITIS C | 2016 |
|
RU2637631C2 |
| IMMUNOBIOLOGICAL AGENT TO ENHANCE CELLULAR RESPONSE AGAINST HEPATITIS C VIRUS | 2023 |
|
RU2811136C1 |
| THERAPEUTIC AGENT FOR TREATING VIRAL HEPATITIS C | 2014 |
|
RU2568872C1 |
| METHOD OF HEPATITIS TREATMENT, COMPOSITION ENHANCING INACTIVATION OF HEPATITIS C VIRUS IN VIVO, PREPARATION FOR HEPATITIS C TREATMENT | 1992 |
|
RU2104010C1 |
| IMMUNOSTIMULATING COMBINATION FOR PREVENTION AND TREATMENT OF HEPATITIS C | 2006 |
|
RU2431499C2 |
| CODING DNA (cDNA) FOR MAKING VIRUS-LIKE PARTICLES OF HEPATITIS C VIRUS, METHOD FOR MAKING VIRUS-LIKE PARTICLES AND BASED PHARMACEUTICAL COMPOSITION | 2007 |
|
RU2375449C2 |
| METHOD FOR INDIVIDUAL PREDICTION OF THERAPEUTIC EFFICACY OF CHRONIC HEPATITIS C WITH PEGYLATED INTERFERON ALPHA AND RIBAVIRIN | 2013 |
|
RU2525159C1 |
| APPLICATION OF SANGLIFERIN FOR TREATING HEPATITIS C VIRUS | 2006 |
|
RU2427372C2 |
| VACCINAL COMPOSITION AGAINST HEPATITIS C VIRUS | 2005 |
|
RU2351363C2 |
| METHOD OF GENERATION OF ANTIGEN-SPECIFIC CYTOTOXIC CELLS ACTIVE AGAINST HEPATITIS B INFECTED CELLS | 2008 |
|
RU2366707C1 |
